Daliya Pencheva
Daliya is a rheumatologist at the Clinic of Rheumatology, University Hospital “St. Ivan Rilski,” Sofia, Bulgaria. She obtained her PhD from the Medical University of Sofia, Bulgaria, with a focus on the management of systemic lupus erythematosus. Daliya is also an assistant professor of pathophysiology at the Department of Physiology and Pathophysiology, Medical University of Sofia. Her major interests include patient-reported outcome measures, quality of life, and treat-to-target strategies. Daliya is a member of the Country Liaison Sub-Committee.
| Poster 0637 | Saturday, 16th November, 2024 10:30 SLE – Diagnosis, Manifestations, & Outcomes Poster I Presenting author: Ciurtin C (UK) Title: Active Implementation of Low Disease Activity State as Treatment Endpoint in a Large Cohort of Adolescents and Young Adults with Childhood Onset Systemic Lupus Erythematosus  This prospective study assessed the feasibility and impact of implementing treat-to-target (T2T) strategies in adolescents and young adults (AYA) with childhood-onset systemic lupus erythematosus (cSLE). The active implementation of T2T strategies increased the percentage of AYA achieving the minimum criteria for clinically low disease activity state (cLLDAS) from 82.7% (N=101) to 91.8% (N=112) over 12 months (P=0.03), indicating that improved clinician-patient education and collaboration can enhance disease control in cSLE. |
| Poster 0659 | Saturday, 16th November, 2024 10:30 SLE – Treatment Poster I Presenting author: Furie R (USA) Title: Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial Post hoc analysis of the NOBILITY trial confirmed that Obinutuzumab, when combined with standard therapy, significantly improves renal response in patients with proliferative lupus nephritis compared to placebo, demonstrating beneficial effects regardless of baseline proteinuria. Further evaluation is ongoing in the Phase III REGENCY trial. |
| Oral 0837 | Saturday, 16th November, 2024 15:00 Abstracts: Antiphospholipid Syndrome Presenting author: Konig M F (USA) Title: Bispecific Autoantigen-T Cell Engagers (BaiTE) to Selectively Target Autoreactive B Cells in Antiphospholipid Syndrome The study developed bispecific autoantigen-T cell engagers (BaiTE) as a precision immunotherapy for antiphospholipid syndrome (APS). BaiTEs selectively target and eliminate autoreactive B cells against beta-2 glycoprotein I (B2GPI), a key driver in APS, while sparing normal B cells. This approach overcomes limitations of current therapies, offering a potent, scalable, and disease-specific treatment without increased infection risk. |
| Oral 1754 | Sunday, 17th November, 2024 15:00 Abstracts: SLE – Treatment I: Cellular Therapy Presenting author: Garantziotis P (Germany) Title: Comparing the Molecular Landscape of the CAR-T Cell and Rituximab Mediated Remission in Systemic Lupus Erythematosus CD19 CAR T cell therapy in refractory systemic lupus erythematosus (SLE) led to significant transcriptional changes, including upregulation of IL-2 production and enhanced apoptotic material clearance, along with downregulation of complement activation, toll-like receptors, and type I interferon signaling. The upregulation of the phagocytosis pathway, uniquely associated with effective clearance of apoptotic material, was observed only with CD19 CAR T cell treatment, distinguishing this therapy from rituximab-induced B cell depletion. |
| Poster 2440 | Monday, 18th November, 2024 10:30 SLE – Treatment Poster III Presenting author: Carrión-Barberà, I (Spain) Title: Ambispective, Multicenter Registry of Treatment with Anifrolumab in Real Life in Patients with Systemic Lupus Erythematosus from Spanish Rheumatology Departments (ANIFRO-Reu): Efficacy, Safety and Patient’s Characteristics In a real-life study of 105 systemic lupus erythematosus (SLE) patients treated with Anifrolumab, significant improvements were observed, with statistically significant differences in the SLEDAI, SLEDAS, physician global assessment, glucocorticoid dose, number of concomitant immunosuppressant drugs used, and the percentage of patients in DORIS remission or a state of low disease activity (LLDAS) after 3 months, suggesting Anifrolumab’s effectiveness in clinical practice for refractory SLE. |
| Oral 2575 | Monday, 18th November, 2024 13:00 Abstracts: SLE – Treatment II: Non-Cellular Lupus Therapeutics Presenting author: Vidal, P (Spain) Title: Can Immunosuppressive Therapy Be Safely Discontinued in Patients with Lupus Nephritis? In a study of lupus nephritis (LN) patients (n=106) who discontinued immunosuppressive (IS) therapy after achieving sustained complete renal response (CRR), 35.8% (n=38) experienced renal relapse (RR). Factors that reduced the risk of RR included more than 48 months of IS therapy, maintaining CRR for over four years, clinical remission according to DORIS guidelines, and gradual tapering of IS therapy. |
| Oral 2601 | Monday, 18th November, 2024 15:00 Abstracts: SLE – Etiology & Pathogenesis Presenting author: Scherlinger, M (France) Title: Platelets Specifically Interact with Remigrating Neutrophils and Promote Immunogenic Cellular Death in Systemic Lupus Platelet-neutrophil aggregates (PNA) are elevated in active systemic lupus erythematosus (SLE) and correlate with disease activity (Spearman’s r = 0.49; p = 0.003). P-selectin signaling in platelets triggers neutrophil activation and immunogenic cell death, contributing to SLE pathogenesis, thus serving as a potential therapeutic target for disease management. |